Last reviewed · How we verify
AD-2281
AD-2281 is a small molecule that targets the PI3K/AKT pathway.
AD-2281 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic breast cancer, Metastatic colorectal cancer.
At a glance
| Generic name | AD-2281 |
|---|---|
| Sponsor | Addpharma Inc. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AD-2281 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. The exact molecular mechanism of AD-2281 is still being researched.
Approved indications
- Metastatic breast cancer
- Metastatic colorectal cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |